GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
TOURS,France,Jan. 7,2025-- GORTEC,known as Head and Neck Radiation Oncology Group,today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab,Bristol Myers Squibb